ALT is set to conduct a virtual meeting over the course of May 27-28, organized by B. Riley. This event will facilitate discussions focusing on the company’s strategic initiatives and future plans. Investors and stakeholders are encouraged to join and gain insights into ALT's performance and potential growth areas.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 6 analysts, the average target price for Altimmune Inc (ALT, Financial) is $20.83 with a high estimate of $25.00 and a low estimate of $12.00. The average target implies an upside of 260.13% from the current price of $5.79. More detailed estimate data can be found on the Altimmune Inc (ALT) Forecast page.
Based on the consensus recommendation from 8 brokerage firms, Altimmune Inc's (ALT, Financial) average brokerage recommendation is currently 1.9, indicating "Outperform" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
ALT Key Business Developments
Release Date: May 13, 2025
- Cash Position: Ended Q1 2025 with $150 million in cash, cash equivalents, and short-term investments, up from $132 million at year-end 2024.
- ATM Facility: Raised $35 million net in Q1 2025, with an additional $16 million since April 1.
- Credit Facility: Entered into a $100 million credit facility with Hercules Capital, with $15 million funding at closing and additional tranches available.
- R&D Expenses: $15.8 million for Q1 2025, down from $21.5 million in Q1 2024.
- G&A Expenses: $6 million for Q1 2025, up from $5.3 million in Q1 2024.
- Net Loss: $19.6 million or $0.26 per share for Q1 2025, compared to $24.4 million or $0.34 per share in Q1 2024.
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
- Altimmune Inc (ALT, Financial) is optimistic about the upcoming readout of their IMPACT Phase 2b NASH trial, expecting to achieve key efficacy and safety objectives.
- The company has entered into a $100 million credit facility with Hercules Capital, enhancing financial flexibility for the development of pemvidutide.
- Altimmune Inc (ALT) is expanding its clinical trials to include alcohol use disorder (AUD) and alcohol liver disease (ALD), addressing significant unmet medical needs.
- The company reported a strong cash position, ending the first quarter with $150 million in cash, cash equivalents, and short-term investments.
- Altimmune Inc (ALT) is preparing for a Phase 3 trial in NASH, with plans to hold an end of Phase 2 meeting with the FDA in the fourth quarter of 2025.
Negative Points
- The company faces risks and uncertainties that could cause actual results to differ materially from forward-looking statements.
- R&D expenses decreased from $21.5 million in Q1 2024 to $15.8 million in Q1 2025, which might indicate reduced investment in research and development.
- Net loss for the first quarter of 2025 was $19.6 million, indicating ongoing financial challenges.
- The company is still in the process of rereading biopsies for the IMPACT trial, which could affect the timeline and outcomes.
- There is uncertainty regarding the placebo response rate in the IMPACT trial, which could impact the trial's success.